Does anyone think that the board is not performing their duty to shareholders by not giving some guidance on that UQ paper? Remember when the Whitehead Institute published the results of their yeast screening for 120,000 or so drugs and found PBT2 a leading hit compound. Prana were right on it with an announcement to the market. Contrast that to now. What has changed? Do they want the price lower?
http://pranabio.com/news/pranas-alzheimers-disease-treatment-strategy-validated-independent-study/#.XGUC3s9KhE4
Does anyone think that the board is not performing their duty to...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $4.734K | 1.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 30295639 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129917446 | 34 |
View Market Depth
| Last trade - 15.44pm 15/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |